Communiqués Revelation Biosciences, Inc.

Actions

REVB

US76135L8046

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 17:08:02 11/08/2026			Varia. 5j.	Varia. 1 janv.
1,100 ^USD	-2,65%		-2,65%	-65,62%

06/08	Revelation Biosciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
10/07	Revelation Biosciences adopte un plan de protection des droits des actionnaires	MT

Communiqués

06/08	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026	AQ
03/08	Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury	AQ
21/07	Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
10/07	Revelation Biosciences Announces Adoption of Stockholder Rights Plan	AQ
01/06	Revelation Biosciences Expands Acute Kidney Injury Advisory Board	AQ
11/05	Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders	AQ
07/05	Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026	AQ
06/04	Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board	AQ
30/03	Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study	AQ
24/03	REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	AQ
19/03	Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference	AQ
08/08/25	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025	BU
24/07/25	Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research	BU
16/07/25	Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study	BU
01/07/25	Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025	BU
29/05/25	Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering	BU
29/05/25	Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering	BU
23/05/25	Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors	BU
08/05/25	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025	BU
29/04/25	Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients	BU
17/03/25	Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells	BU
13/03/25	Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference	BU
06/03/25	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024	BU
26/02/25	Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients	BU
24/02/25	Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval	BU